Biofil Chemicals & Pharmaceuticals
Biofil Chemicals & Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Biofil Chemicals & Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Biofil Chemicals & Pharmaceuticals Ltd trades at a P/E of 21.20× and P/B of 2.74×.
Valuation
Profitability
Growth
Financial Health
Biofil Chemicals & Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Biofil Chemicals & Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
Biofil Chemicals & Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹58.57 Cr and reported EPS of ₹1.71.
Biofil Chemicals & Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Biofil Chemicals & Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Biofil Chemicals & Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Biofil Chemicals & Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Biofil Chemicals & Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Biofil Chemicals & Pharmaceuticals Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Very low debt-to-equity ratio (0.03) indicates strong financial stability.
Reported impressive 1318% quarter-on-quarter profit growth, signaling a turnaround.
P/E ratio (22.30) significantly lower than sector P/E (133.45), suggesting undervaluation.
Diversified business model across pharmaceuticals, chemicals, and contract manufacturing.
Achieved moderate 7.63% revenue growth over the past five years.
What can break it.
Very low ROE (3.03%) and ROCE (4.12%) indicate inefficient capital utilization.
Latest quarterly sales declined significantly by 23.80% to 6.43 Cr.
Thin operating profit margin (0.63%) makes company vulnerable to cost fluctuations.
Negligible FII/DII holdings (0.00%, 0.08%) indicate lack of institutional confidence.
Negative EPS growth of 14.32% over five years is concerning.
What would change my mind.
Trim if P/E re-rates above 28. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 14.51. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 9%. The operating engine is no longer compounding capital efficiently.
Biofil Chemicals & Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Biofil Chemicals & Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Biofil Chemicals & Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Biofil Chemicals & Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
Biofil Chemicals & Pharmaceuticals Ltd last traded at ₹36.25 with an intraday range of ₹35.56–₹37.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹36.25| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 41.19 | +4.94 | +13.64% |
| R3 | 39.25 | +3.00 | +8.29% |
| R2 | 38.38 | +2.13 | +5.87% |
| R1 | 37.31 | +1.06 | +2.93% |
| PIVOT | 36.44 | 0.19 | 0.51% |
| CURRENT | 36.25 | — | — |
| S1 | 31.49 | -4.76 | -13.12% |
| S2 | 33.43 | -2.82 | -7.77% |
| S3 | 34.50 | -1.75 | -4.84% |
| S4 | 35.37 | -0.88 | -2.42% |
BIOFILCHEM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 35.56 ~ 36.33
Trading Inside opening range
Biofil Chemicals & Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Biofil Chemicals & Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Biofil Chemicals & Pharmaceuticals Ltd stood at 36.2% of traded volume, against a 20-day average of 50.5%.
Biofil Chemicals & Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Biofil Chemicals & Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Biofil Chemicals & Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 45 documents below.
Copy of Newspaper Publication
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication pursuant to Regulation 47 of SEBI (Listing…
Disclosure under SEBI Takeover Regulations
KETAN SHAH has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Updates
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30 of the SEBI (Listing Obligations and…
Copy of Newspaper Publication
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Submission of Publication in Newspaper pursuant to SEBI circular for…
Updates
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Intimation regarding SEBI Circular dated January 30, 2026 Ease of Doing…
Biofil Chemicals & Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Biofil Chemicals & Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
Biofil Chemicals & Pharmaceuticals insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| Niyati Shah | Insider | 06 Jun 2025 | buy | +4.94 L | — | — |
Biofil Chemicals & Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Biofil Chemicals & Pharmaceuticals has declared, sequenced by announce and record date.
Biofil Chemicals & Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Biofil Chemicals & Pharmaceuticals Ltd: business, sector, key facts.
What Biofil Chemicals & Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Biofil Chemicals & Pharmaceuticals Ltd operates in the Healthcare, listed as NSE: BIOFILCHEM, BSE: 524396.
Biofil Chemicals and Pharmaceuticals Limited (Biofilchem) is an Indian company primarily engaged in the manufacturing and trading of pharmaceuticals and chemicals. Their business model encompasses two key divisions: Pharmaceuticals and Chemicals. This dual approach allows them to cater to a broader market, encompassing both the production of essential drug components and the finished pharmaceutical products themselves.
The Chemical division focuses on the production and supply of a range of basic drugs and chemical compounds. Their product portfolio includes a variety of inorganic salts crucial in pharmaceutical formulations, such as sodium chloride, potassium chloride, and sodium citrate. They also manufacture organic compounds like diethylcarbamazine citrate, used in anthelmintic medications. In addition to these, Biofilchem produces key excipients, including ferrous sulphate (in both dried and standard forms) and ferrous fumarate, which are frequently used in the manufacture of iron supplements. The company also supplies microcrystalline cellulose, a common pharmaceutical excipient for tablet formulation, and dicyclomine hydrochloride, an antispasmodic agent.
Beyond the core chemical production, Biofilchem also contributes to the packaging side of the pharmaceutical industry. They manufacture plastic drippers and caps, essential components for packaging liquid medications, providing a comprehensive supply chain solution for pharmaceutical companies. This vertical integration strategy strengthens their position within the market and potentially offers improved cost control.
Furthermore, Biofilchem offers job work services, acting as a contract manufacturer for other pharmaceutical companies. This facet of their business involves producing pharmaceutical drugs on behalf of third parties, leveraging their existing manufacturing capabilities to expand their revenue streams and diversify their client base. This service likely contributes to their overall profitability and ensures consistent utilization of their production facilities.
In summary, Biofilchem's business is multifaceted, ranging from the production of essential chemical raw materials and excipients to the manufacturing of finished pharmaceutical products and packaging components. The company's integrated approach, encompassing manufacturing, trading, and contract manufacturing, allows for a diversified and relatively resilient business model within the Indian pharmaceutical market. Established in 1985 and headquartered in Indore, India, Biofilchem has developed a strong foundation within the pharmaceutical and chemical landscape.
Questions investors ask about Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?
The current share price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is ₹36.25. Today, the stock has gained by ₹0.85 (2.40%), trading in a range of ₹35.56 to ₹37.5. The stock opened at ₹36.3 with a trading volume of 2,34,649 shares.
02Is Biofil Chemicals & Pharmaceuticals Ltd stock a good investment for long-term?
Biofil Chemicals & Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹58.57 crores, P/E ratio of 21.20, ROE of 13.81%, and ROCE of 4.12%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Biofil Chemicals & Pharmaceuticals Ltd stock?
The 52-week high price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is ₹0, while the 52-week low is ₹0. Currently trading at ₹36.25, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Biofil Chemicals & Pharmaceuticals Ltd stock at the current price?
Whether to buy Biofil Chemicals & Pharmaceuticals Ltd stock at ₹36.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 21.20 and P/B ratio of 2.74. Today's performance shows a gain of 2.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Biofil Chemicals & Pharmaceuticals Ltd and when is the next dividend?
Biofil Chemicals & Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹36.25, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 21.20, P/B Ratio: 2.74, ROE: 13.81%, ROCE: 4.12%, Dividend Yield: 0.00%, EPS: ₹1.71, Book Value: ₹13.21, and Debt-to-Equity: 14.01. The company's market cap stands at ₹58.57 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Biofil Chemicals & Pharmaceuticals Ltd stock performing today in the market?
Biofil Chemicals & Pharmaceuticals Ltd stock opened at ₹36.3 and is currently trading at ₹36.25, showing a gain of ₹0.85 (2.40%). The intraday high is ₹37.5 and low is ₹35.56. The trading volume stands at 2,34,649 shares, indicating moderate market participation today.
08What is the P/E ratio of Biofil Chemicals & Pharmaceuticals Ltd and what does it indicate?
Biofil Chemicals & Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 21.20, which means investors are willing to pay ₹21.20 for every ₹1 of earnings. With an EPS of ₹1.71, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy